Clinical Trials Directory

AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia

The purpose of this study is to see if we can improve the remission and survival rates for children with AML/MDS and the ways that fungal infections are diagnosed in patients with AML/MDS. We also will study the effects of clofarabine, sorafenib and valproic acid in high risk patients and how leukemia cells react to chemotherapy during treatment.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Cytarabine
  • drug : Clofarabine
  • drug : Etoposide
  • drug : Daunorubicin

Phase: Phase 3

Eligibility

Ages Eligible For Study:

N/A - 21 Years

Inclusion Criteria

- Age less than or equal to 21 years at time of study entry. - No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less ) for hyperleukocytosis. - Written informed consent according to institutional guidelines - Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment - Male and female participants must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem Onc CRAs
650-723-5535
Recruiting

Footer Links: